Conventional adjuvant therapy of cancer often involves repeated doses of chemotherapy and radiation which can be very toxic and debilitating for the patient. Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, states that immunotherapy-based cancer treatment is potentially much more targeted and effective, with little or none of the side effects of chemotherapy and radiation. This type of treatment would greatly improve the quality of life of cancer patients. Furthermore, immunotherapy has the potential to cause tumor regression in patients where other treatment has failed. Dr. Michael Har-Noy says Immunovative Therapies is pursuing funding for a Phase II/III trial of its lead product, AlloStim™.